FUJIFILM Pharmaceuticals U.S.A. Inc reported on Wednesday that FUJIFILM Corporation has ramped up its manufacturing capacity at FUJIFILM Toyama Chemical Co Ltd to increase production of its influenza antiviral drug Avigan Tablet (generic name: favipiravir) for treating patients with COVID-19.
In conjunction, Fujifilm is allocating additional capacity at its Japanese FUJIFILM Wako Pure Chemical Co Ltd facility for production of pharmaceutical intermediates used in the manufacture Avigan. The company has also established partnerships with domestic and overseas companies for various manufacturing processes to source raw materials and pharmaceutical substances.
Avigan selectively inhibits viral RNA polymerase necessary for influenza virus replication. Due to this mechanism of action, Avigan may have an antiviral effect on the SARS-CoV-2 coronavirus.
Fujifilm expects to increase the monthly production of Avigan up to 100,000 treatment courses by July 2020, approximately 2.5 times more compared to the beginning of March, with production further increased to 300,000 treatment courses by September 2020.
The Japanese government reportedly plans to stockpile 2 million treatment courses of Avigan as part of its emergency economic package.
Peak Pharma Commercial Partners establishes Resilia Pharmaceuticals and starts operations
Nephron Pharmaceuticals Corporation receives USFDA approval over Ketorolac Tromethamine Injection
Amring gains global rights to LYSTEDA
Troy Medicare Closes USD 10m Series B Led by AXA Venture Partners
Breckenridge wins final FDA approval for Pomalidomide Capsules ANDA
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Cipla reports sharp rise in demand for COVID-19 drug remdesivir in India
Sandoz ships pantoprazole sodium to Civica Rx
Russia's Pharmasyntez seeks permission to produce COVID-19 drug without patent